Benzinga | Nov 17, 2020 08:09AM EST

Athenex To Present Data On Oral Paclitaxel And Encequidar At 2020 San Antonio Breast Cancer Symposium Dec. 9

* Spotlight poster on updated PFS and OS data from the pivotal Phase 3 clinical trial of oral paclitaxel in metastatic breast cancer

BUFFALO, N.Y., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that oral paclitaxel and encequidar ("oral paclitaxel") data will be presented in four separate poster presentations at the 2020 San Antonio Breast Cancer Symposium (SABCS) to be held virtually December 8-11. Presentations will include, from the pivotal Phase 3 clinical trial of oral paclitaxel in metastatic breast cancer (MBC), a spotlight poster on progression-free survival (PFS) and overall survival (OS), and posters on neuropathy (CIPN), and management of gastrointestinal (GI) side effects. An additional poster explores oral paclitaxel in the treatment of cutaneous angiosarcoma of the breast.

The symposium will also feature an immersive Athenex Oncology virtual exhibit experience with distinct hubs for CIPN, Medical Affairs, and the Facing MBC Together program.

Details of the oral paclitaxel presentations are as follows:



Spotlight Poster Presentation

Abstract Title: Oral Paclitaxel and Encequidar (oPac+E) versus IV Paclitaxel (IVPac) in the treatment of metastatic breast cancer (mBC) patients (Study: KX-ORAX-001)

Session: Spotlight Poster Discussion 1

Program Number: PD1-08

Date and Time: Wednesday, December 9, 2020, at 4:00 PM to 5:15 PM Central Time (CT)

For more information, please visit: https://www.sabcs.org/Program/Spotlight-Sessions/Spotlight-Poster-Discussion-1

Abstracts selected for spotlight poster presentation will only have titles posted to the SABCS website until the embargo lifts on December 9, 2020, when the complete abstract will post online.



Additional Poster Presentations

Abstract Title: A phase 2 study of Oral Paclitaxel and Encequidar (oPac+E) in the treatment of cutaneous angiosarcoma: the breast angiosarcoma group

Program Number: PS13-05

Session: Poster Session 13

Date and Time: Wednesday, December 9, 2020, at 800 AM CT

For more information, please visit: https://www.sabcs.org/Program/Poster-Sessions/Poster-Session-13

Abstract Title: Lower rates of neuropathy with Oral Paclitaxel and Encequidar (oPac+E) compared to IV Paclitaxel (IVPac) in treatment of metastatic breast cancer (mBC): Study KX-ORAX-001

Program Number: PS13-06

Session: Poster Session 13

Date and Time: Wednesday, December 9, 2020, at 8:00 AM CT

For more information, please visit: https://www.sabcs.org/Program/Poster-Sessions/Poster-Session-13

Abstract Title: Oral Paclitaxel and Encequidar (oPac+E) in the treatment of metastatic breast cancer (mBC): Management of gastrointestinal adverse events (GI AE). Study KX-ORAX-001

Program Number: PS13-11

Session: Poster Session 13

Date and Time: Wednesday, December 9, 2020, at 800 AM CT

For more information, please visit: https://www.sabcs.org/Program/Poster-Sessions/Poster-Session-13